Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 14
1988 6
1989 6
1990 10
1991 9
1992 13
1993 8
1994 20
1995 32
1996 34
1997 33
1998 50
1999 33
2000 22
2001 30
2002 20
2003 33
2004 27
2005 31
2006 33
2007 22
2008 23
2009 18
2010 19
2011 24
2012 18
2013 13
2014 8
2015 13
2016 17
2017 18
2018 19
2019 18
2020 26
2021 29
2022 20
2023 15
2024 19
2025 21
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

772 results

Results by year

Filters applied: . Clear all
Page 1
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Cornely OA, et al. N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094. N Engl J Med. 2007. PMID: 17251531 Free article. Clinical Trial.
We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole and fluconazole or itraconazole groups; death from any cause and time to death were secondary end points. RESULTS: A total of 304 pa …
We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole …
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.
Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen LA, Ter Horst S, Dreesen E, Geukens T, Engelen MM, Landeloos E, Geldhof V, Ceunen H, Debaveye B, Vandenberk B, Van der Linden L, Jacobs S, Langendries L, Boudewijns R, Do TND, Chiu W, Wang X, Zhang X, Weynand B, Vanassche T, Devos T, Meyfroidt G, Janssens W, Vos R, Vermeersch P, Wauters J, Verbeke G, De Munter P, Kaptein SJF, Rocha-Pereira J, Delang L, Van Wijngaerden E, Neyts J, Verhamme P. Liesenborghs L, et al. EBioMedicine. 2021 Apr;66:103288. doi: 10.1016/j.ebiom.2021.103288. Epub 2021 Mar 19. EBioMedicine. 2021. PMID: 33752127 Free PMC article. Clinical Trial.
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19. ...In …
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical …
Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.
Shenoy MM, De A, Shah B, Das A, Saraswat A, Lahiri K, Yadav S, Sarda A, Chakraborty D, J D, Kamat S, Doshi Y, Gonsalves N, Choudhary A, Dhoot D, Mahadkar N, Bhushan S, Gadkari R, Barkate H. Shenoy MM, et al. Drug Des Devel Ther. 2023 Sep 21;17:2899-2908. doi: 10.2147/DDDT.S421583. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 37766823 Free PMC article. Clinical Trial.
INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 …
INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is co …
Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma.
Chu WY, Fahal AH, Ahmed ES, Bakhiet SM, Bakhiet OE, Fahal LA, Mohamed AA, Mohamedelamin ESW, Bahar MEN, Attalla HY, Siddig EE, Mhmoud NA, Musa AM, Oyieko P, Egondi T, Brüggemann RJ, Hata K, Strub-Wourgaft N, Alves F, Nyaoke BA, Zijlstra EE, Dorlo TPC. Chu WY, et al. J Infect Dis. 2025 Sep 15;232(3):e518-e528. doi: 10.1093/infdis/jiaf279. J Infect Dis. 2025. PMID: 40433693 Free PMC article. Clinical Trial.
BACKGROUND: The first clinical trial on eumycetoma was recently conducted in Sudan, comparing oral fosravuconazole, prodrug of active ravuconazole, with the standard-of-care oral itraconazole. Building on this trial, the present study aimed to characterize the pharmacokine …
BACKGROUND: The first clinical trial on eumycetoma was recently conducted in Sudan, comparing oral fosravuconazole, prodrug of active ravuco …
Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway.
Zhang W, Bhagwath AS, Ramzan Z, Williams TA, Subramaniyan I, Edpuganti V, Kallem RR, Dunbar KB, Ding P, Gong K, Geurkink SA, Beg MS, Kim J, Zhang Q, Habib AA, Choi SH, Lapsiwala R, Bhagwath G, Dowell JE, Melton SD, Jie C, Putnam WC, Pham TH, Wang DH. Zhang W, et al. Mol Cancer Ther. 2021 Oct;20(10):1904-1915. doi: 10.1158/1535-7163.MCT-20-0638. Epub 2021 Aug 10. Mol Cancer Ther. 2021. PMID: 34376577 Free PMC article. Clinical Trial.
Itraconazole, an FDA-approved antifungal, has antitumor activity against a variety of cancers. We sought to determine the effects of itraconazole on esophageal cancer and elucidate its mechanism of action. Itraconazole inhibited cell proliferation and induced …
Itraconazole, an FDA-approved antifungal, has antitumor activity against a variety of cancers. We sought to determine the effects of …
Cold atmospheric plasma therapy for Malassezia folliculitis: Laboratory investigations and a randomized clinical trial.
Wang N, Yan T, Mei X, Liu J, Lei Y, Yang C. Wang N, et al. Skin Res Technol. 2024 Jul;30(7):e13850. doi: 10.1111/srt.13850. Skin Res Technol. 2024. PMID: 38979986 Free PMC article. Clinical Trial.
At week 2, success was achieved by 40.0% of subjects in the CAP group versus 58.3% in the itraconazole group (p = 0.199). The negative direct microscopy rates of follicular samples were 56.0% in the CAP group versus 66.7% in the itraconazole group (p = 0.444). ...Th …
At week 2, success was achieved by 40.0% of subjects in the CAP group versus 58.3% in the itraconazole group (p = 0.199). The negativ …
Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole.
Wingfield AB, Fernandez-Obregon AC, Wignall FS, Greer DL. Wingfield AB, et al. Br J Dermatol. 2004 Jan;150(1):119-26. doi: 10.1111/j.1365-2133.2004.05643.x. Br J Dermatol. 2004. PMID: 14746625 Clinical Trial.
OBJECTIVES: The aim of this study was to compare the efficacy of itraconazole, terbinafine and fluconazole with that of griseofulvin after 4 weeks of therapy. ...The fluconazole group experienced no significant remission, and remission was of short duration in the itrac …
OBJECTIVES: The aim of this study was to compare the efficacy of itraconazole, terbinafine and fluconazole with that of griseofulvin …
Itraconazole Improved Bronchial Wall Thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial.
Aligolighasemabadi F, Mirsadraee M, Sadeghdoust M, Ghaffari S, Sarafraz Yazdi M, Naghibi S, Hashemi Attar A. Aligolighasemabadi F, et al. Iran J Allergy Asthma Immunol. 2023 Feb 20;22(1):1-11. doi: 10.18502/ijaai.v22i1.12000. Iran J Allergy Asthma Immunol. 2023. PMID: 37002624 Free article. Clinical Trial.
Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. Similarly, lumen area and radius increased significantly in both the prednisolone and itraconazole groups. Itraconazole led to …
Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. S …
Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.
Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Agarwal R, et al. Mycoses. 2013 Sep;56(5):559-70. doi: 10.1111/myc.12075. Epub 2013 Mar 18. Mycoses. 2013. PMID: 23496375 Clinical Trial.
A total of 31 patients (mean age, 37 years) were randomised to itraconazole (n = 17) or the control (n = 14) group. The number of patients showing overall response was significantly higher in the itraconazole group (76.5%) vs. the control (35.7%) group (P = 0.02). . …
A total of 31 patients (mean age, 37 years) were randomised to itraconazole (n = 17) or the control (n = 14) group. The number of pat …
Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.
Badorrek P, Diefenbach C, Kögler H, Eleftheraki A, Seitz F, Hohlfeld JM. Badorrek P, et al. Clin Transl Sci. 2024 Aug;17(8):e13891. doi: 10.1111/cts.13891. Clin Transl Sci. 2024. PMID: 39175217 Free PMC article. Clinical Trial.
Five phase I trials of BI 1291583 in healthy subjects are presented: a single-rising-dose study (NCT03414008) and two multiple-rising-dose studies (NCT03868540 and NCT04866160) assessing the safety, tolerability, pharmacodynamics, and pharmacokinetics of BI 1291583; a food effect …
Five phase I trials of BI 1291583 in healthy subjects are presented: a single-rising-dose study (NCT03414008) and two multiple-rising-dose s …
772 results